Efficacy and safety of adalimumab as the first- and second-line biologic therapy for children with juvenile idiopathic arthritis under four years of age

Publication date: Available online 21 April 2020Source: The Egyptian RheumatologistAuthor(s): Ekaterina Alexeeva, Tatyana Dvoryakovskaya, Rina Denisova, Tatyana Sleptsova, Kseniya Isaeva, Alexandra Chomahidze, Anna Fetisova, Anna Mamutova, Alina Alshevskaya, Andrey Moskalev
Source: The Egyptian Rheumatologist - Category: Rheumatology Source Type: research